Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration

Guétard, Denise; Greco, Raffaella; Gonzalez, Minerva Cervantes; Celli, Susanna; Kostrzak, Anna; Langlade‐Demoyen, Pierre; Sala, F.; Wain‐Hobson, Simon; Sala, Monica

doi:10.1016/j.vaccine.2008.06.059

Cited by 31 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…79 Nonetheless, while cellular responses may be absent in such cases, induction of humoral responses have been reported regardless of the immune status. 80 Given the effectiveness of poliovirus and rotavirus vaccines, it is clear that swallowing of vaccine can function as a means of protection against viruses with significant GI pathogenesis. However, evidence supporting the effectiveness of the intraintestinal route for vaccines against HIV or SIV is still insufficient.…”

Section: Oral Vaccinationmentioning

confidence: 99%

Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection

Poles

Alvarez²,

Hioe³

2014

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

CD4+ T cells in the mucosa of the gastrointestinal (GI) tract are preferentially targeted and depleted by HIV. As such, the induction of an effective anti-HIV immune response in the mucosa of the GI tract-through vaccination-could protect this vulnerable population of cells. Mucosal vaccination provides a promising means of inducing robust humoral and cellular responses in the GI tract. Here we review data from the literature about the effectiveness of various mucosal vaccination routes-oral (intraintestinal/tonsilar/sublingual), intranasal, and intrarectal-with regard to the induction of immune responses mediated by cytotoxic T cells and antibodies in the GI mucosa, as well as protective efficacy in challenge models. We present data from the literature indicating that mucosal routes have the potential to effectively elicit GI mucosal immunity and protect against challenge. Given their capacity for the induction of anti-HIV immune responses in the GI mucosa, we propose that mucosal routes, including the nonconventional sublingual, tonsilar, and intrarectal routes, be considered for the delivery of the next generation HIV vaccines. However, further studies are necessary to determine the ideal vectors and vaccination regimens for these routes of immunization and to validate their efficacy in controlling HIV infection. HIV Epidemics and Treatment HIV infection has resulted in the death of millions since the early 1980s, and has been responsible for significant morbidity and decline in quality of life for millions more. Each year, an estimated 50,000 people are newly infected with the virus in the United States alone, adding to the 34 million currently living with the virus worldwide.

show abstract

Section: Oral Vaccinationmentioning

confidence: 99%

Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection

Poles

Alvarez²,

Hioe³

2014

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…The great genetic variety among HIV-1 subtypes, high mutation rate and biological properties of HIV-1 regulatory proteins by avoiding immune response (Cueno et al, 2010) significantly worsen the process of developing an efficient vaccine. Various HIV proteins have been expressed in plant systems so far: HIV-1 p24 in tobacco Perez-Filgueira et al, 2004b) and A. thaliana (Lindh et al, 2014), HIV 1 P55 Gag polyprotein in tobacco chloroplasts (Scotti et al, 2009) and tobacco plants both in full length and truncated form (Meyer et al, 2008), HIV-1 Tat in potato (Kim and Langridge, 2004a) and tomato (Cueno et al, 2010), HIV-1 Nef in tobacco (Marusic et al, 2007) and N. benthamiana (Lombardi et al, 2009;Circelli et al, 2010), HIV-1 CA capsid protein VLPs in Lycium barbarum (Du et al, 2004), HIV-1/HBV fusion protein has been expressed in tobacco Guetard et al, 2008) and A. thaliana . Tat regulatory element of the simian-HIV-1 virus (SHIV 89.6 Tat) has also been expressed in potato , fused to cholera toxin subunit B.…”

Section: Hivmentioning

confidence: 99%

Production of vaccines for treatment of infectious diseases by transgenic plants

Ledl

Luthar

2016

AAS

View full text Add to dashboard Cite

Since the first pathogen antigen was expressed in transgenic plants with the aim of producing edible vaccine in early 1990s, transgenic plants have become a well-established expression system for production of alternative vaccines against various human and animal infectious diseases. The main focus of plant expression systems in the last five years has been on improving expression of well-studied antigens such as porcine reproductive and respiratory syndrome (PRRSV), bovine viral diarrhea disease virus (BVDV), footh and mouth disease virus (FMDV), hepatitis B surface antigen (HBsAg), rabies G protein, rotavirus, Newcastle disease virus (NDV), Norwalk virus capsid protein (NVCP), avian influenza virus H5N1, Escherichia coli heat-labile enterotoxin subunit B (LT-B), cholera toxin B (CT-B), human immunodeficiency virus (HIV), artherosclerosis, ebola and anthrax. Significant increases in expression have been obtained using improved expression vectors, different plant species and transformation methods.Key words: transgenic plants; vaccine production; recombinant proteins; antibodies; infectious diseases; risk assessment IZVLEČEK ZDRAVLJENJE NALEZLJIVIH BOLEZNI S CEPIVI PRIDOBLJENIMI S TRANSGENIMI RASTLINAMIPridobivanje aktivnih sestavin za cepiva s transgenimi rastlinami se je začelo v devetdesetih letih prejšnjega stoletja. Od takrat se transgene rastline uveljavljajo kot alternativni ekspresijski sistem za sintezo aktivnih komponent za cepiva proti številnim humanim in živalskim nalezljivim boleznim. V zadnjih petih letih je bil glavni poudarek razvoja namenjen optimizaciji rastlinskih ekspresijskih sistemov za dobro proučene antigene, kot so virus prašičjega respiratornega in reproduktivnega sindroma, virus goveje virusne diareje, virus parkljevke, površinski antigen hepatitisa B, G protein virusa stekline, rotavirus, virus atipične kokošje kuge, plaščni protein Norwalk virusa, sev ptičje gripe H5N1, temperaturno nestabilna B podenota enterotoksina Escherischia coli, kolera toksin B, HIV, arterioskleroza, ebola in antraks. Uporaba optimiziranih transformacijskih metod in ekspresijskih vektorjev v kombinaciji s primerno izbrano rastlinsko vrsto je v večini naštetih primerov vodila do opaznega izboljšanja sinteze posameznih učinkovin.

show abstract

“…Transgenic potato plants expressing HPV 16 L1-VLPs have been generated and feeding transgenic potato tubers to mice orally induces an anti-HPV 16 L1 antibody responses, but this is mostly transient [58]. HIV1/HBV-VLPs expressed in Nicotianatabacum and Arabidopsis thaliana have been orally administered to mice to elicit anHIV1-specific cellular immune response [59]. HIV1 gag-VLPs transgenically produced in tobacco plastids are formed with the same shape as those produced in baculovirus expression systems [60].…”

Section: Plantsmentioning

confidence: 99%

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Kato¹,

Deo²,

Park

et al. 2012

J Biotechnol Biomaterial

View full text Add to dashboard Cite

Virus-like particles (VLPs), which mimic the structure of authentic virus, are of significant importance owing to their wide ranging applications. VLPs have the potential to serve as candidate vaccine in addition to subunit vaccines and also serve as a nano-bioparticle scaffold for displaying complex foreign proteins. Here, we review different methods available to produce VLPs with various host expression systems including from microorganisms to mammalian cells and the current potential of silkworms as producers of these VLPs. Recently, silkworms have been used for efficient production of VLPs too in addition to mass production of recombinant proteins, which have contributed to molecular structural analysis, molecule-molecule interactions in biology and biotechnology.

show abstract

Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration

Cited by 31 publications

References 48 publications

Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection

Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection

Production of vaccines for treatment of infectious diseases by transgenic plants

Functional Virus-Like Particles Production Using Silkworm and Their Application in Life Science

Contact Info

Product

Resources

About